Jump Financial LLC Buys Shares of 154,842 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

Jump Financial LLC purchased a new stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 154,842 shares of the company's stock, valued at approximately $1,075,000. Jump Financial LLC owned approximately 0.25% of Monte Rosa Therapeutics as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Monte Rosa Therapeutics by 54.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 24,100 shares of the company's stock worth $128,000 after buying an additional 8,500 shares during the period. State Street Corp grew its holdings in Monte Rosa Therapeutics by 8.1% during the 3rd quarter. State Street Corp now owns 687,577 shares of the company's stock worth $3,644,000 after acquiring an additional 51,493 shares during the period. Barclays PLC raised its position in shares of Monte Rosa Therapeutics by 395.1% during the 3rd quarter. Barclays PLC now owns 54,508 shares of the company's stock valued at $289,000 after acquiring an additional 43,499 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Monte Rosa Therapeutics by 23.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,044,689 shares of the company's stock valued at $5,538,000 after purchasing an additional 197,247 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of Monte Rosa Therapeutics by 38.2% during the third quarter. JPMorgan Chase & Co. now owns 18,543 shares of the company's stock worth $98,000 after purchasing an additional 5,125 shares during the period. Institutional investors and hedge funds own 79.96% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on GLUE shares. Wedbush restated an "outperform" rating and set a $17.00 target price (up previously from $15.00) on shares of Monte Rosa Therapeutics in a report on Thursday, March 20th. Wells Fargo & Company reduced their price objective on shares of Monte Rosa Therapeutics from $11.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Friday, March 21st. Finally, Lifesci Capital assumed coverage on shares of Monte Rosa Therapeutics in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $19.00 target price for the company.

Monte Rosa Therapeutics Trading Down 3.4 %

Shares of GLUE traded down $0.18 during midday trading on Friday, reaching $5.05. The stock had a trading volume of 313,429 shares, compared to its average volume of 776,560. Monte Rosa Therapeutics, Inc. has a one year low of $3.21 and a one year high of $12.40. The firm has a market cap of $310.32 million, a PE ratio of -2.76 and a beta of 1.53. The firm has a 50 day simple moving average of $5.36 and a 200-day simple moving average of $6.56.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.60. The business had revenue of $14.00 million for the quarter, compared to analyst estimates of $43.73 million. As a group, research analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.49 EPS for the current fiscal year.

Insider Transactions at Monte Rosa Therapeutics

In other news, Director Chandra P. Leo bought 10,000 shares of the stock in a transaction dated Monday, March 24th. The shares were bought at an average price of $5.84 per share, for a total transaction of $58,400.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at approximately $58,400. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.50% of the stock is currently owned by corporate insiders.

Monte Rosa Therapeutics Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.